Alan Bitonti, Ph.D., most recently served as the vice president of research at the Syntonix subsidiary of Biogen Idec. He earlier held senior research roles at Syntonix and was responsible for the discovery and preclinical development of two clotting factors that have been approved for the treatment of hemophilia A and B. Prior to 1999, Alan held positions of increasing management responsibility in discovery research at Hoechst Marion Roussel (1995-1998, oncology research), Marion Merrell Dow (1990-1995, cancer biology) and Merrell Dow Pharmaceuticals (1981-1990, parasite biology). He received a Ph.D. in pharmacology from Ohio State University and trained as a staff fellow in the Laboratory of Cellular Metabolism of the National Heart, Lung and Blood Institute, part of the National Institutes of Health.